StreetAlpha.app
Home › Stocks › RANI

Rani Therapeutics Holdings, Inc. (RANI)

$0.56
▲ +3.54%
LAST CLOSE · NOV 17

Rani Therapeutics develops the RaniPill capsule, an oral delivery technology for drugs and biologics that are now often given by injection. It last closed at $0.56 on Nov 17, up 3.54% on the day.

AI Auto Pilots
Is RANI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$6.6M
+448.7% vs a year ago
Net income
−$32.5M
−493.0% margin
EPS (diluted)
−$0.07
Free cash flow
−$23.2M
−352.7% margin
Balance sheet
Cash & equivalents
$3.6M
At Sep 30
Shareholder equity
$34.0M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $2.7M$2.7MFY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $1.0M$1.0MFY2024FY2025: $1.6M$1.6MFY2025

From RANI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated RANI in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 972.6% upside

Based on 1 analyst who set a price target on RANI in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $0.56.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $0.56
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Chardan CapitalMaintained
Oct 22Buy$6
Chardan CapitalInitiated
Aug 18Buy$6
Canaccord GenuityMaintained
May 20Buy$5
DateFirmActionRatingPrice target
Oct 22Chardan CapitalMaintainedBuy$6
Aug 18Chardan CapitalInitiatedBuy$6
May 20Canaccord GenuityMaintainedBuy$5
Loading…

Technical Analysis

RANI · as of the Nov 17 close · updated after every close
Downtrend

The stock is 2% below its 20 day and 24% below its 50 day average. It is 58% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 42). The nearest support is the Pivot S1 at $0.54, and the nearest resistance the Pivot at $0.56.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 7.6%/day
Key levels
$1.9952 week high+255.4%
$0.89200 day average+58.9%
$0.82Swing high (Aug 12)+46.4%
$0.74100 day average+32.1%
$0.6950 day average+23.2%
$0.58Pivot R1+3.6%
$0.5720 day average+1.8%
$0.56Pivot+0.0%
$0.56Last close
$0.54Pivot S1−3.6%
$0.51Swing low (Nov 5)−8.9%
$0.5052 week low−10.7%
Indicators
RSI (14)41.51Middle of its rangeNeutral
MACD-0.04Above its signal lineBullish
Stochastic34.0Middle of its rangeNeutral
ADX (14)45.3Strong downtrend
Williams %R-49.4Oversold below −80, overbought above −20Neutral
CCI (20)-40.5Oversold below −100, overbought above 100Neutral
Rate of change+0.7%Change over 10 sessionsBullish
ATR (14)$0.04Typical daily range, 7.7% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RANI

What happened before

See how RANI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RANI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RANI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RANI in the last 90 days.

Loading…

See today’s whale options flow across the market →

RANI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲28 buying vs 21 selling
  • ▲Shares held by funds +2.6%
  • ▲Funds holding +1
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding6867+1.5%
In funds' top 1000–
Held by funds–––
New / increased8 / 2011 / 15+7.7%
Reduced / sold out14 / 713 / 16−27.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RANI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RANI is in one of them and how their past RANI trades turned out.

RANI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RANI in an article yet. Here's the latest on the wider market.

About Rani Therapeutics Holdings

Rani Therapeutics is a biotherapeutics company based in San Jose, California. It is developing the RaniPill capsule, a delivery technology designed to let drugs and biologics such as antibodies and peptides be taken orally instead of by injection. The company is advancing its own oral drug candidates and is seeking partnerships with biopharmaceutical companies to use its technology. Its intended customers include patients, physicians, and healthcare systems, and it has no approved products for sale yet.

Headquarters
Fremont, CA